Drug Profile
Research programme: antiallergics - CAT/Xerion
Alternative Names: Antiallergics research programme - CAT/XerionLatest Information Update: 08 May 2008
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology; Xerion Pharmaceuticals
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity
Most Recent Events
- 14 Jul 2006 No development reported - Preclinical for Allergy in Germany (unspecified route)
- 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
- 22 Aug 2002 Preclinical trials in Allergy in Germany (unspecified route)